Open official notice

Lorazepam Injection, USP, 2mg mL, 1 mL vial (NDC 0641-6044-01), packaged in 25 x 1 mL Vials per carton (NDC 0641-6044-25), Rx only

Official notice

24 May 2023

RecallScope risk estimate:MediumFDA

An official FDA notice concerns Lorazepam Injection, USP, 2mg mL, 1 mL vial (NDC 0641-6044-01), packaged in 25 x 1 mL Vials per carton (NDC 0641-6044-25), Rx only. Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C. Published 2023-05-24.

What to do now

This recall has been terminated. See the official FDA notice for the latest status.

Units affected

1,352,475

Recall number

D-0574-2023

Official notice

2023-05-24

The hazard

Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C.

How to check if you’re affected

Compare the product name and identifiers below with the item you own. Check the official notice for the affected products and next steps.

Event Ids

92320

Recall Numbers

D-0574-2023

Checked manually this time?

Follow brands and keywords in the app to receive alerts for matching official notices.

Turn on recall alerts

Affected products

Product 1

Lorazepam Injection, USP, 2mg/mL, 1 mL vial (NDC 0641-6044-01), packaged in 25 x 1 mL Vials per carton (NDC 0641-6044-25), Rx only, Manufactured by West-Ward, Eatontown, NJ 07724.

Units affected

1,352,475

Hazard

Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C.

Where it was sold

Retailer information is not currently available in RecallScope. Check the official notice for distribution details.

Location 1

US · United States

Affected area 1

US · United States

Company & contacts

Manufacturer

Hikma Pharmaceuticals USA Inc.

Phone

Not provided

Brand: Hikma Pharmaceuticals. Contact: Hikma Pharmaceuticals USA Inc..

Source & status

Source

Tier

official

Category

Health

Official classification

Class II

Recall details

Recall number

D-0574-2023

Event ID

92320

Units affected

1,352,475

Status

terminated

Source tier

official

Documents, notices & source

See the official notice and source documents for full details.

View full official notice
Something wrong on this page?

Weekly recall digest

Get next week’s recalls before you need them.

One email every Monday with official-source recalls for your country, and nothing else. Unsubscribe from any email.

The digest arrives once a week. For matching recall alerts after notices are processed, get the app.

This recall was published 24 May 2023. The next one won’t wait for you to search.

RecallScope checks listed publishers for the brands and VINs you follow, and can alert you when a matching notice is processed.

apple-buttongoogle-button